其产品线还包括其他 ADC。此次收购正值 AbbVie 在失去独占权 (LOE) 后面临其重磅药物 Humira 的激烈竞争之际。这家大型制药公司一直财力雄厚。

其产品线还包括其他 ADC。此次收购正值 AbbVie 在失去独占权 (LOE) 后面临其重磅药物 Humira 的激烈竞争之际。这家大型制药公司一直财力雄厚。在收购 ImmunoGen 仅一个月后，AbbVie 就大举投资 Cerevel Therapeutics 及其以神经科学为重点的产品线（包括分别用于治疗阿尔茨 ...

But Humira is not just a small jewel for AbbVie – it’s the Hope diamond. This was spelled out in a FirstWord Pharma article entitled: “Spotlight on: On the back of 4Q results, AbbVie and ...

Because of Humira's efficacy and the fact that it's a complex biologic, AbbVie charges as much as $60,000 per year for it, depending on patient weight and dosing frequency. As a result ...

With Humira's LOE looming in 2023, AbbVie stands to lose billions of dollars in revenues. Estimating Humira's likely losses to biosimilars in the US in 2023 and onward is more art than science ...

CEO Gonzalez wryly noted during the Q2 2018 earnings call that AbbVie started 5.5 years ago as the Humira company. Today AbbVie has several approved therapies that are significant revenue ...

(Reuters) - AbbVie Inc's blockbuster arthritis drug Humira barely beat Wall Street sales forecasts, raising concerns about its future viability as a cash cow and sending the drugmaker's shares ...

(Reuters) - AbbVie , the pharmaceuticals business spun off earlier this month by Abbott Laboratories , forecast 2013 earnings in line with Wall Street forecasts but slowing sales growth for Humira ...

But when it comes to Abbvie ’s Humira, there’s a clear picture showing company sales have paid off the research and development costs multiple times over while still leaving behind billions in ...

At AbbVie, there's no doomsday scenario talk despite a looming expiration date on Humira, the best-selling drug in the world. That's because the company is a case study in the lengths a ...

Lawmakers in Congress busily marking up bills on pharmacy middlemen this week might want to pay heed to AbbVie’sABBV1.38 ... of the arthritis therapy Humira—the highest-grossing drug ever ...